daytrade diaries... november 10, page-12

Neuren is working in an very interesting field.
Neutral regeneration peptides and methods for their use in treatment of brain damage, traumatic brain injury.
Sofar has been no announcement but expected unless they announce that the trials that should have already started, actually have. More recently developments since 1.July:
- Neuren received US$14mill funding from the US Armee, total of US$18.7mill
- Costs for the phase 2 trial to be funded by the US Armee
- Total US Armee funding represents A$0.09 per share non- dilutive funding !!!
- US FDA approves for phase 2 trial
- US FDA grants "Fast Track" status

NEU is one if not the Top Pick in the Bio Sector.